MétaCan
Menu
Back to cohort
Record W3048064409 · doi:10.1111/all.14547

Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines

2020· review· en· W3048064409 on OpenAlexaff
Ioana Agache, Claudio Rocha, Ana Margarida Pereira, Yang Song, Pablo Alonso‐Coello, Iván Solà, Jessica Beltrán, Margarita Posso, Cezmi A. Akdiş, Mübeccel Akdiş, Knut Brockow, Tomás Chivato, Stefano Del Giacco, Thomas Eiwegger, Kilian Eyerich, Ana M. Giménez‐Arnau, Jan Gutermuth, Emma Guttman‐Yassky, Marcus Maurer, Graham S. Ogg, Peck Y. Ong, Liam O’Mahony, Jürgen Schwarze, Thomas Werfel, Carlos Canelo‐Aybar, Óscar Palomares, Marek Jutel

Bibliographic record

VenueAllergy · 2020
Typereview
Languageen
FieldMedicine
TopicUrticaria and Related Conditions
Canadian institutionsSickKids FoundationHospital for Sick ChildrenUniversity of Toronto
FundersMedical Research CouncilNational Institute for Health and Care Research
KeywordsOmalizumabMedicineDermatology Life Quality IndexCochrane LibraryChronic urticariaInternal medicineConfidence intervalQuality of life (healthcare)PediatricsImmunoglobulin EImmunology

Abstract

fetched live from OpenAlex

This systematic review evaluates the efficacy and safety of omalizumab for chronic spontaneous urticaria (CSU). PubMed, Embase, and Cochrane Library were searched for RCTs. Critical and important CSU-related outcomes were considered. The risk of bias and the certainty of the evidence were assessed using GRADE. Ten RCTs including 1620 subjects aged 12 to 75 years old treated with omalizumab for 16 to 40 weeks were evaluated. Omalizumab 150 mg does not result in clinically meaningful improvement (high certainty) of the urticaria activity score (UAS)7 (mean difference (MD) -5; 95%CI -7.75 to -2.25), and the itch severity score (ISS)7 (MD -2.15; 95% CI -3.2 to -1.1) does not increase (moderate certainty) quality of life (QoL) (Dermatology Life Quality Index (DLQI); MD -2.01; 95%CI -3.22 to -0.81) and decreases (moderate certainty) rescue medication use (MD -1.68; 95%CI -2.95 to -0.4). Omalizumab 300 mg results in clinically meaningful improvements (moderate certainty) of the UAS7 (MD -11.05; 95%CI -12.87 to -9.24), the ISS7 (MD -4.45; 95%CI -5.39 to -3.51), and QoL (high certainty) (DLQI; MD -4.03; 95% CI -5.56 to -2.5) and decreases (moderate certainty) rescue medication use (MD -2.04; 95%CI -3.19 to -0.88) and drug-related serious AEs (RR 0.77; 95%CI 0.20 to 2.91).

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.014
metaresearch head score (Gemma)0.050
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Systematic review · Consensus signal: Systematic review
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.014
Threshold uncertainty score0.074

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0140.050
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0110.012
Bibliometrics0.0090.006
Science and technology studies0.0010.001
Scholarly communication0.0030.003
Open science0.0020.002
Research integrity0.0030.002
Insufficient payload (model declined to judge)0.0060.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.067
GPT teacher head0.355
Teacher spread0.288 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designSystematic review
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations95
Published2020
Admission routes1
Has abstractyes

Explore more

Same venueAllergySame topicUrticaria and Related ConditionsFrench-language works237,207